Myocardial infarction (MI) is the most serious complication of coronary artery disease. In the last decades the progress in treatment of MI has led to a significant improvement of prognosis. Nonetheless, despite a generally high prevalence of guideline-recommended therapies, especially percutaneous revascularization, the mortality rates are still significant.
1,2
Atrial fibrillation is the most common heart arrhythmia. It seems that each consecutive population-based study concerning atrial fibrillation reports higher prevalence of the disease. Currently in the United States it is reported that 2% of people < 65 years old have atrial fibrillation, reaching 9% in older patients. 3 We expect a rapid publication of data showing this is still an underestimation. Current guidelines recommend anticoagulation in all atrial fibrillation patients with moderate to high ischaemic stroke risk. 4 Both these conditions are a significant threat for the patient as well as a diagnostic and therapeutic challenge for the physician. We are fully capable of coping with these diseases on their own. Are we prepared well enough to do so when the two diseases combine?
This combination in fact is not uncommon. In MI patients the occurrence of atrial fibrillation reaches 21%. 5 Simultaneously, the annual rate of MI in atrial fibrillation patients can be as high as 2.5%. 6 Recent data corroborates that atrial fibrillation is related to increased risk of MI, especially in patients with no history of coronary artery disease. 7, 8 Nonetheless, data on atrial fibrillation and MI is scarce. Especially, the management of new onset atrial fibrillation in the peri-MI period with regard to antithrombotic regimen remains controversial. Only recently have the ST-elevation myocardial infarction guidelines adopted the indication to introduce anticoagulation for patients with new-onset peri-MI atrial fibrillation (class of recommendation IIaC). 9 It is important to remember that this is based on expert consensus, without support in MI related studies. With the universal need for real-life observational data, evidence such as presented by Jortveit et al. is of utmost importance. 10 Although the study was not designed to tackle this particular issue, its findings corroborate the message conveyed by the guidelines' experts.
While the abovementioned presumption that atrial fibrillation and MI combined pose a difficult challenge might be controversial, how else could the data presented by Jortveit et al. be interpreted? Myocardial infarction guidelines in essence universally recommend coronary angiography for all MI patients -at some time during their hospitalization. Data published from the PL-ACS and SWEDEHEART registries show an adoption of invasive strategy in contemporary all-comer MI patients at the level of 90%.
11,12 Jortveit et al. report a significant adoption of invasive strategy and percutaneous intervention in a general all-comer Norwegian population. However, in the relatively small subset of atrial fibrillation patients the reported rate of coronary angiography (45.8%), with no clear explanation, is alarming. Likewise, the prevalence of percutaneous revascularization was worrisomely lowonly 30% of the analysed atrial fibrillation population were offered this form of treatment. Is atrial fibrillation reason enough to vindicate such a conservative approach, contradictory to contemporary guidelines? Of course, atrial fibrillation is related to numerous comorbidities and generally inferior cardiovascular status, yet by no means justifies such refraining from offering optimal treatment modalities.
While revascularization is at the basis of acute coronary syndromes, anticoagulation is at the centre of atrial fibrillation treatment to prevent cerebrovascular incidents. In the study by Jortveit et al. the proportion of atrial fibrillation patients discharged after MI with anticoagulation barely exceeding the 50% mark was low, yet not lower than in other available data.
fibrillation population was diagnosed with new-onset peri-MI arrhythmia. Moreover, contemporary evidence that prognosis of MI patients with new-onset atrial fibrillation is related to inferior outcomes is scarce.
Still, why does this undertreatment happen? Atrial fibrillation itself seems a frail explanation. However, when we consider this arrhythmia a surrogate of older age and comorbidities this may be more understandable. While the guidelines do not support it, physicians worldwide are more prone to deliver less aggressive treatment in the elderly and morbid populations. This approach is understandable, especially since the guidelines are mostly based on clinical trials a priori excluding these patients. The recently published applicability study of the COMPASS trial (rivaroxaban for coronary artery disease) showed that merely 53% of real-life patients would be eligible for the clinical study. 14, 15 Unpublished data from our centre shows that this number might be even lower, around one-third of the general population. With this in mind, how sure can we actually be that more aggressive antithrombotic treatment in a multi-morbid elderly population would lead to a similar benefit as reported in clinical trials? It seems that the risk-to-benefit ratio would be dubious. Perhaps in the near future we will witness a withdrawal from the most aggressive antithrombotic regimen, especially 'triple' therapy, as suggested by recent studies and guidelines. 16, 17 Each large observational study allows us to better understand the disease in question. Jortveit et al. show that atrial fibrillation in MI patients is related to inferior survival as well as significantly increased combined risk of death or stroke. The study provides us with an important insight that this subset of patients requires our stringent attention. While the authors report no differences in outcome between patients with atrial fibrillation on admission and new-onset atrial fibrillation, this remains an open question for future studies. Moreover, despite a large population and low adoption of anticoagulation the authors did not report significant differences in the rates of stroke itself -another question in need of answer in future studies. It would also be interesting to see a comparison of outcomes in the non-atrial fibrillation and the atrial fibrillation subgroups on full guideline-recommended antithrombotic treatment.
With the ageing population undergoing treatment for acute coronary syndromes we will be forced to tackle the older and multi-morbid patients, with high risk of both stroke and bleeding complications. A proper antithrombotic regimen must be aimed at optimal management of both these factors. This is even more challenging as these patients are usually omitted from clinical trials. This highlights yet again the undisputable value of observational data, especially in specific patient subsets. The analysis by Jortveit et al. should, among others, be commended for the bold statement that even in a developed country the reallife is not as pristine as we would sometimes like to imagine. Such analyses should force us to consider whether in specific patient subsets the treatment we apply is optimal and whether the knowledge derived from evidence based medicine is applicable in a given clinical scenario.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
